Eledon Pharmaceuticals (ELDN) director June Lee reports 3,430 RSU shares

Rhea-AI Filing Summary

Eledon Pharmaceuticals director June Lee reported the vesting and settlement of restricted stock units into common shares. On January 10, 2026, 3,430 restricted stock units converted into 3,430 shares of common stock at a price of $0 per share, leaving Lee with 3,430 common shares held directly after the transaction.

The footnote explains that these shares came from restricted stock units granted on January 10, 2025, which vested 100% on January 10, 2026 on a one-for-one basis into common stock. Following the conversion, the derivative position in these restricted stock units was reduced to zero.

Insider Trade Summary

3,430 shares exercised/converted

Mixed 2 txns

Insider Lee June

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	3,430	$0.00	--
Exercise	Common Stock	3,430	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Common Stock — 3,430 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee June

(Last) (First) (Middle)

C/O ELEDON PHARMACEUTICALS, INC.

19800 MACARTHUR BLVD STE. 250

(Street)

IRVINE CA 92612

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Eledon Pharmaceuticals, Inc. [ ELDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/10/2026		M		3,430(1)	A	$0	3,430	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/10/2026		M			3,430	(1)	(1)	Common Stock	3,430	$0	0	D

Explanation of Responses:

1. Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026.

	/s/ Paul Little, as attorney-in-fact for June Lee	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Eledon Pharmaceuticals (ELDN) report for June Lee?

The filing reports that June Lee, a director of Eledon Pharmaceuticals, had 3,430 restricted stock units convert into 3,430 shares of common stock on January 10, 2026 at $0 per share.

How many Eledon Pharmaceuticals common shares does June Lee hold after this Form 4 transaction?

After the reported transaction, June Lee beneficially owns 3,430 shares of Eledon Pharmaceuticals common stock in direct ownership.

What is the origin and vesting schedule of June Lee’s RSUs in Eledon Pharmaceuticals (ELDN)?

The footnote states that the restricted stock units were issued on January 10, 2025 and vested 100% on January 10, 2026, settling into common stock on a one-for-one basis.

What does transaction code "M" mean in this Eledon Pharmaceuticals Form 4?

In this Form 4, code "M" indicates the exercise or conversion of derivative securities, here the conversion of 3,430 restricted stock units into 3,430 common shares.

Is June Lee’s ownership in Eledon Pharmaceuticals direct or indirect after this transaction?

The filing identifies June Lee’s 3,430 common shares as held in direct ownership, with no nature of indirect beneficial ownership listed.